1. Home
  2. POM vs RNTX Comparison

POM vs RNTX Comparison

Compare POM & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

POM

POMDOCTOR LIMITED American Depositary Shares

N/A

Current Price

$0.31

Market Cap

47.2M

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.52

Market Cap

42.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POM
RNTX
Founded
2015
2001
Country
China
United States
Employees
N/A
10
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.2M
42.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
POM
RNTX
Price
$0.31
$1.52
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
629.7K
116.8K
Earning Date
05-03-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$1.02
52 Week High
$6.43
$2.22

Technical Indicators

Market Signals
Indicator
POM
RNTX
Relative Strength Index (RSI) 52.54 63.75
Support Level $0.28 $1.08
Resistance Level $0.43 $1.59
Average True Range (ATR) 0.04 0.17
MACD 0.00 0.03
Stochastic Oscillator 68.97 69.49

Price Performance

Historical Comparison
POM
RNTX

About POM POMDOCTOR LIMITED American Depositary Shares

Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: